Prevention of Postoperative Bleeding in Subcapital Femoral Fractures

NCT ID: NCT02150720

Last Updated: 2016-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

161 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main hypothesis of this clinical trial is that the use of intra-articular tranexamic acid and the fibrin glue plus usual hemostasis will reduce at least a 25% the postoperative blood loss with respect to usual hemostasis in patients undergoing subcapital femoral fractures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Fracture Blood Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tranexamic acid

Tranexamic acid, 1g intra-articular before closing the surgery wound

Group Type EXPERIMENTAL

Tranexamic Acid

Intervention Type DRUG

1g intra-articular before closing the wound surgery

Electrocauterization

Intervention Type PROCEDURE

Coagulation blood from vessels by means of a electrocautery.

Fibrin glue

One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,

Group Type EXPERIMENTAL

Fibrin glue

Intervention Type DRUG

5mL intra-articular before closing the wound surgery

Electrocauterization

Intervention Type PROCEDURE

Coagulation blood from vessels by means of a electrocautery.

Usual hemostasia

Electrocauterization

Group Type ACTIVE_COMPARATOR

Electrocauterization

Intervention Type PROCEDURE

Coagulation blood from vessels by means of a electrocautery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic Acid

1g intra-articular before closing the wound surgery

Intervention Type DRUG

Fibrin glue

5mL intra-articular before closing the wound surgery

Intervention Type DRUG

Electrocauterization

Coagulation blood from vessels by means of a electrocautery.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amchafibrin Evicel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years
* Patients with unilateral subcapital femoral fracture
* Patients requiring hip replacement (total or partial)
* Signed informed consent from the patient or legal representative

Exclusion Criteria

* Known allergy to fibrin glue and tranexamic acid
* Multiple fractures
* Pathological fractures
* Contraceptives or estrogen therapy
* Use of blood salvage during surgery
* History compatible with thromboembolic disease:

* Cerebral vascular accident
* Ischemic heart disease (myocardial infarction, angina )
* Deep vein thrombosis
* Pulmonary Embolism
* Peripheral arterial vasculopathy
* Patients with thrombogenic arrhythmias
* Patients with cardiovascular stents
* Prothrombotic alterations in coagulation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MJ Martínez-Zapata, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Iberoamerican Cochrane Centre. Research Institut Hospital de la Santa Creu i Sant Pau. IIB Sant Pau

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Germans Trias i Pujol de Badalona

Badalona, Barcelona, Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

Site Status

Hospital Clinic

Barcelona, Barcelona, Spain

Site Status

Parc Taulí

Sabadell, Barcelona, Spain

Site Status

Hospital Universitari Mútua Terrassa

Terrassa, Barcelona, Spain

Site Status

Hospital Universitari Terrassa-Consorci Sanitari de Terrassa

Terrassa, Barcelona, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Martínez-Zapata MJ, Jordán M, Aguilera X, Cánovas E, Urrutia G (en nombre del grupo TRANEXFER). Estudio prospectivo multicéntrico de una cohorte para evaluar la calidad de vida de pacientes intervenidos de fractura subcapital de fémur. Trauma 2014; 25 (4): 188-195.

Reference Type RESULT

Merchan-Galvis A, Posso M, Canovas E, Jordan M, Aguilera X, Martinez-Zapata MJ. Quality of life and cost-effectiveness analysis of topical tranexamic acid and fibrin glue in femur fracture surgery. BMC Musculoskelet Disord. 2022 Aug 31;23(1):827. doi: 10.1186/s12891-022-05775-y.

Reference Type DERIVED
PMID: 36045358 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mapfre.com/fundacion/html/revistas/trauma/v25n4/docs/v25n4.pdf

Publication of quality of life (subgroup of patients)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EC11-341

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2011-006278-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

SA/12/AYU/456

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IIBSP-FAT-2011-103

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Blood Loss After Early TXA in Hip Fractures.
NCT04488367 UNKNOWN EARLY_PHASE1
Tranexamic Acid (TXA) in Hip Arthroscopy
NCT05710146 WITHDRAWN PHASE3